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ABSTRACT A high peptidylglycine ac-amidating mono-
oxygenase (PAMase) activity has been measured in the pan-
creas of neonatal rats. A significant fraction of this activity is
contained in the beta cells of the islets of Langerhans and is
colocalized with thyrotropin-releasing hormone (TRH) and its
precursor in secretory granules. The ontogenetic variation of
PAMase activity in the pancreas parallels that of TRH con-
centrations, suggesting that this enzymatic activity is directly
related to TRH biosynthesis. In addition, PAMase activity is
able to generate TRH when incubated with <Glu-His-Pro-Gly,
a tetrapeptide present as a repetitive sequence in the TRH
precursor. The perinatal evolution of the TRH precursor levels
in the pancreas is similar to that of PAMase activity (unpub-
lished results). Thus, the neonatal rat pancreas offers an
endocrine model in which the levels of a neuropeptide precur-
sor and an enzyme activity, involved in the posttranslational
modification of this precursor, are similarly regulated. Our
results suggest also that a fraction of PAMase activity may be
produced outside of the beta cells and related to the biosyn-
thesis of COOH-terminally amidated peptide(s) other than
TRH. The ontogenetic changes in PAMase activity imply that
the synthesis of this peptide(s) is high during the neonatal
period, decreasing thereafter.
Thyrotropin-releasing hormone (TRH, <Glu-His-Pro-NH2)
was initially isolated in the hypothalamus (1, 2); however, its
distribution is ubiquitous, including the whole brain and the
gastrointestinal tract (3). The ontogenetic pattern ofTRH in
the pancreas of the rat is peculiar, with the highest levels just
after birth, decreasing rapidly toward low levels in the adults
(4-6). Despite the early isolation ofTRH, its biosynthesis has
remained obscure until recently (7). Results from different
groups (including ours) support the hypothesis that TRH, like
other neuropeptides, arises from the posttranslational pro-
cessing of a large precursor protein (8, 9). This hypothesis,
strongly reinforced by the determination of the cDNA se-
quence of a portion of the TRH precursor in amphibian skin
(10), has been confirmed by the characterization of a cDNA
clone coding for the precursor of TRH in the rat hypothala-
mus (11).
TRH is a COOH-terminally a-amidated tripeptide. Amino
acid sequence data for many peptide precursors (including
the incomplete sequence of the TRH precursor in amphibian
skin) indicate that peptides with COOH-terminal glycine are
the intermediate precursors to COOH-terminally a-amidated
peptides (12). The mechanisms of the posttranslational mod-
ifications of the TRH precursor have not been established.
First, they may involve proteolytic cleavages that give rise to
the tetrapeptide Gln-His-Pro-Gly. Then, TRH may be gen-
erated after the spontaneous cyclization of the NH2-terminal
amino acid and the enzymatic amidation of proline, with the
glycine residue acting as the amide donor under the action of
a peptidylglycine a-amidating monooxygenase (PAMase).
The hypothetical pathway of TRH described above is sup-
ported by studies on the maturation of the prooxytocin-
neurophysin precursor (13, 14). PAMase activity has been
characterized in the intermediate and anterior lobes of the
pituitary (15-17), in the mouse pituitary corticotropic tumor
cells (At-T20) (18), as well as in the hypothalamus, where it
may be involved in the biosynthesis of several bioactive
peptides, such as TRH, oxytocin, and vasopressin (19).
PAMase activity is barely detectable in the pancreas of the
adult rat (20).
In this study, we present evidence that PAMase* activity
is high in the rat pancreas during the neonatal period and
follows a pattern similar to that ofTRH levels in this tissue.
Our results suggest also that a significant fraction of pancre-
atic PAMase activity is involved in the biosynthesis ofTRH.
MATERIALS AND METHODS
Animals. Female Long Evans rats were bred in our
laboratory and their litters were used in the experiments. The
day sperm was identified in the vaginal smear was designated
day 0 of pregnancy (gestational length, 22 days) and the day
ofbirth was designated day 0 of life. The animals were housed
in individual cages at 23 ± 2°C under controlled light
(0700-2000 hr) daily and fed Purina Chow and tap water ad
libitum.
Amidation Assay. Amidation activity was measured on
crude mitochondrial/secretory granules prepared from fresh-
ly dissected pancreata collected from 19-day fetuses as well
as from 1- to 90-day-old rats. The pancreata were homoge-
nized at 4°C (in a Teflon/glass homogenizer, 10 strokes) in 10
vol of 0.3 M sucrose/0.02 M Tris HCl, pH 7.4. The homog-
enate was centrifuged at 400 x g for 10 min at 4°C to sediment
nuclei and cell debris. Supernatant was then centrifuged at
12,000 x g for 30 min at 4°C. The pellet containing the
mitochondrial/secretory granules was resuspended in 0.5 ml
of 10 mM phosphate buffer (pH 7.0), submitted to three
consecutive freeze-thaw cycles, and stored until assay for
amidating activity. The protein concentrations in these prep-
arations were determined according to Bradford (21) using
the protein assay kit from Bio-Rad. Since PAMase activity in
the pituitary gland is dependent on CUS04, ascorbate, and
molecular oxygen (22), we have tested the influence of all
Abbreviations: TRH, thyrotropin-releasing hormone; a-MSH, a-
melanocyte-stimulating hormone; PAMase, peptidylglycine a-ami-
dating monooxygenase; TRH-OH, <Glu-His-Pro-OH.
*Since peptide a-amidating activity in the pancreas displays the same
characteristics as PAMase activity in other tissues, it will be
referred to as PAMase in this report.
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three agents on PAMase activity from pancreas. The addition
of 3 mM ascorbate and 40 AM CuS04 was optimal for
PAMase activity. However, since the optimal amount of
CuS04 to be added in the assay appears to be critical
according to the tissue (20), all of the measurements of
PAMase activity were performed with various amounts of
CuS04 ranging from 10 to 180 AM. The rate of the a-
amidation reaction was also determined in the presence of an
air atmosphere (control) or in the presence of a constant
stream of helium to replace most of the molecular oxygen.
The PAMase assay was performed at 370C for 4 hr in a final
volume of 0.05 ml using the method of Eipper et al. (22). The
following reagents were added to each tube: 3 mM ascorbate,
100 ,gg of catalase per ml; 45 Ag of tissue protein; 25 AM
D-Tyr-Val-Gly (Novabiochem, Laufelfingen, Switzerland),
125I-labeled D-Tyr-Val-Gly (18,000-20,000 cpm), and increas-
ing amounts of CuS04 (10-180 MM). All of the reagents were
prepared in 0.12 M sodium N-[tris(hydroxymethyl)methyl]-
aminoethanesulfonic acid (pH 7.4) (Merck, Darmstadt,
F.R.G.). The labeled substrate and product were separated
on a 1-ml column of sulfopropyl Sephadex C25-120
(Pharmacia, Uppsala) equilibrated in 10 mM phosphate
buffer (pH 5.0). After a 12-ml wash in the same buffer, elution
was performed with 0.5 M NaCl in 0.05 M phosphate buffer
(pH 5.0). The a-amidation activity was directly related to the
rate of conversion of 1251-labeled D-Tyr-Val-Gly into 125I1
labeled D-Tyr-Val-NH2 and was expressed as pmol/hr per pAg
of protein of D-Tyr-Val-NH2 generated from D-Tyr-Val-Gly.
All samples were assayed in duplicate and generally deviated
<5% from the mean.
Determination of the Conversion Rate of <Glu-His-Pro-Gly
into <Glu-His-Pro-NH2 (TRH) by Neonate Rat Pancreatic
Preparation. As suggested in the Introduction, the tetrapep-
tide <Glu-His-Pro-Gly is a putative natural substrate for
PAMase activity in pancreatic secretory granules. Thus, it
was of interest to test whether pancreatic PAMase was able
to convert <Glu-His-Pro-Gly into TRH. The tetrapeptide
<Glu-His-Pro-Gly (synthesized for us by J. Van Rietschoten
and C. Granier, Institut National de la Sante et de la
Recherche Medicale, U 172, Marseille, France) (25 ,M) was
incubated with a pancreatic mitochondrial/secretory granule
preparation from 3-day-old rats under optimal assay condi-
tions at 37°C for 0-4 hr. The reaction was stopped by the
addition of 0.5 ml 5 M acetic acid, followed by boiling for 10
min. The samples then were centrifuged at +40C (2000 x g,
10 min) and the supernatant was evaporated to dryness. TRH
levels in the tubes were determined by radioimmunoassay
(23).
Cellular Localization of PAMase Activity in the Rat Pan-
creas. To study the cellular localization of PAMase activity in
the neonate rat pancreas, 1-day-old rats were injected with
streptozotocin, a drug displaying specific cytotoxicity toward
the beta cells of the endocrine pancreas (24). Streptozotocin
(Sigma) was dissolved extemporaneously in 0.1 M sodium
citrate (pH 4.5) and injected i.p. into 1-day-old rats (150
mg/kg). Control rats received the same volume (0.1 ml) of the
vehicle. At the age of 4 and 6 days, the rats were sacrificed,
and their pancreata were collected and prepared for mea-
surement ofPAMase activity. In the group of streptozotocin-
treated rats, only the pancreata from rats with glycemia
>3.50 g/liter were used for the experiment.
Subcellular Localization of PAMase Activity in the Neonate
Rat Pancreas. A pancreatic mitochondrial/secretory granule
preparation was obtained as described, except that the initial
homogenization was performed after exposure to DNase I (26
,ug/ml at room temperature for 5 min). This preparation was
layered on the top of 11 ml of 33.3% isoosmotic Percoll
(Pharmacia, Upsala) in 0.3 M sucrose/0.02 M Tris HCl, pH
7.4. After centrifugation at +40C (65,000 x g, 60 min), 0.4-ml
fractions were collected by puncturing the tubes and were
assayed for PAMase activity (22), TRH (23), and TRH
precursor (9).
Measurement of TRH and Its Precursor. TRH levels were
determined by a radioimmunoassay (23) in subcellular frac-
tions from 3-day-old rat pancreas and in extracts from rat
pancreata obtained at different developmental stages. Pan-
creatic extracts were prepared as follows. Freshly dissected
rat pancreata were boiled for 15 min in 10 vol of 5 M acetic
acid, cooled on ice, homogenized in a Teflon/glass homog-
enizer (10 strokes), and centrifuged at 2500 x g (40C, 15 min).
The acidic and clear supernatant was evaporated to dryness
in a Speed Vac apparatus (Savant, Hicksville, NY). TheTRH
antiserum shows 1% crossreaction with <Glu-His-Pro-Gly
and no crossreaction (<0.01%) with the putative metabolites
of TRH, <Glu-His-Pro-OH (TRH-OH), and histidylproline-
diketopiperazine.
The levels of TRH precursor were determined in the
subcellular fractions from 3-day-old rat pancreas as described
by Ouafik et al. (9). Briefly, the samples were appropriately
diluted and subjected to a sequential enzymatic treatment by
L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated
trypsin (50 jig/ml) for 2 hr at 370C (Worthington) and
carboxypeptidase A (Sigma) for 2 hr at 370C. The enzymes
were successively heat-inactivated (950C, 20 min). The se-
quence TRH-OH generated by the enzymatic treatment of
the precursor for TRH was measured by a specific radio-
immunoassay (6). TRH precursor levels were expressed as
the difference between the values of TRH-OH-immunoreac-
tive material measured in the different fractions after and
prior to sequential enzymatic treatment. The antiserum
anti-TRH-OH shows no significant crossreaction with TRH
and <Glu-His-Pro-Gly (<0.0001).
TRH and TRH-OH used as standards in the radioim-
munoassays have been purchased from Sigma.
RESULTS
Preliminary Characterization of PAMase Activity in the
Neonate Rat Pancreas. The crude mitochondrial/secretory
granule preparations from neonatal rats displayed a high
PAMase activity. This activity was linear in time for up to 4
hr and linear in content of protein for up to 170 ,ug (results not
shown).
This activity, like enzymatic PAMase activity described in
other tissues (22), required the presence of CuS04, ascor-
bate, and molecular oxygen and is therefore referred to as
pancreatic PAMase in the rest of the text.
Ascorbate requirement was the same as in other tissues,
but the optimal concentration of CuS04 in pancreatic prep-
arations (close to 40 ,uM) was four and eight times higher than
in the anterior (10 ,M) and neurointermediate (5 ,uM) lobe of
the pituitary gland, respectively. CuS04 concentrations >50
,uM resulted in an inhibition of this activity. In the absence of
molecular oxygen in the reaction mixture, there was a 60%
decrease of the pancreatic PAMase activity. The velocity of
the enzymatic reaction appeared to be of the same order of
magnitude in the 3-day-old rat pancreas (4 pmol/hr per ,ug of
protein) and in the adult rat pituitary gland (10 and 2 pmol/hr
per ,tg of protein in the anterior and neurointermediate lobe,
respectively).
Ontogenetic Evolution of Pancreatic PAMase Activity. As
shown in Fig. 1 [and as published by different groups (4-6)],
immunoreactive TRH concentrations in the rat pancreas
reached a peak 4 days after birth and then decreased rapidly
toward the minute levels found in adults. PAMase activity
was already detectable in the pancreata from 19-day fetuses.
The highest PAMase activity was observed in 3-day-old rats.
Thereafter, PAMase activity decreased rapidly with a 50%
reduction between the third and fourth day of life. Then a
plateau was reached between the fifth and eighth day;
Proc. Natl. Acad. Sci. USA 84 (1987)
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FIG. 1. Ontogenesis ofPAMase (A- -A) activity and TRH (m *-)
levels in rat pancreas. The PAMase activity was measured under the
conditions described in the text, using a constant amount of pancire-
atic mitochondrial/secretory granule preparation (45 Ug of protein)
and CUS04 (40 ,uM) at all stages investigated. TRH was measured by
radioimmunoassay in pancreatic extracts as described by Dutour et
al. (6). The results are expressed as mean ± SEM (six to eight
determinations at each developmental stage).
thereafter, a further decrease was observed. When the rats
were 21 days old, the PAMase activity in the pancreas
represented 9% of the activity observed in 3-ay-old rats. In
adult rats, this activity was very low, barely detectable
(<0.05 pmol/hr per jug of protein). The peak of PAMase
activity preceded that of TRH by 1 day. Then TRH levels
decreased more rapidly than PAMase activity.
Ability of Pancreatic PAMase Activity to Convert the
Tetrapeptide <Glu-His-Pro-Gly into TRH. As shown in Table
1, high levels of immunoreactive TRH were generated after
incubation of <Glu-His-Pro-Gly with the mitochondrial/
secretorygranule preparation, indicating that the high
PAMase activity in the pancreas of 3-day-old rats may be
responsible for the high rate of synthesis ofTRH at this stage.
However, the levels of TRH generated under these condi-
tions were lower ter d hat expected on the basis of the
conversion rate of t PMabeled D-Tyr-Val-Gly intop25aclas
beled D-Tyr-Val-NH2. Indeed, inosday-old rats, the amida-
tion activity was lower by a factor of 7.8 when measured with
<Glu-His-Pro-Gly rather than D-Tyr-Val-Gly as a substrate.
Table 1. Generation ofTRHafter incubation of crude
detochondrial/secretory granule preparation from
3-day-old rat pancreas with the tetrapeptide
ui< Glu-His-Pro-Gly
TRH content,
Incubation conditions fmol of TRH per tube
Without tetrapeptide,
0min 8 ± 2.17
With tetrapeptide
0 min 76 ± 21.6
4hr 2240±134
Incubation times are indicated. Results are expressed as mean ±
SEM of four determinations. The increased TRH concentrations
after addition of <Glu-His-Pro-Gly and before incubation are due to
the crossreactivity of the TRH antiserum with the tetrapeptide.
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Table 2. Effect of streptozotocin treatment on the pancreatic
PAMase activity of 4- and 6-day-old rats
PAMase activity,
pmol/hr per jug of protein
Age, days Control Streptozotocin-treated
4 2.5 (6) 1.27 (6)
6 1.17 (5) 0.52 (4)
D-Tyr-Val-NH2 was generated from D-Tyr-Val-Gly. Results are
expressed as the mean of two determinations. The difference
between extreme values and the mean was <5%. The number of
animals per determination is given in parentheses.
Cellular Localization of Pancreatic PAMase Activity. As
shown in Table 2, the treatment with streptozotocin induced
a 50% and 55% decrease of PAMase activity in 4- and
6-day-old rats, respectively. Since streptozotocin toxicity is
specific for beta cells, these data suggest that about one-half
of the PAMase activity is present in these cells.
Subcellular Localization of Pancreatic PAMase Activity.
After subcellular fractionation of 3-day-old rat pancreas
homogenates over an isoosmotic Percoll density gradient, the
distributions of PAMase activity and of TRH and TRH
precursor (the putative product and substrate of pancreatic
PAMase, respectively) were shown to display similar pro-
files, characterized by a single peak containing >80% ofthese
activities (Fig. 2). This peak corresponded to organelles of
density between 1.06 and 1.08 and also contained most of
insulin immunoreactivity (results not shown).
DISCUSSION
TRH concentrations in the pancreata from neonatal rats are
very high during a short, transient period (4-6). The physi-
ological role of TRH in the pancreas of neonates is not
understood; however, the rapid changes in TRH levels in the
rat pancreas during the neonatal period make this tissue an
interesting model for studying the mechanisms and regulation
of TRH biosynthesis. Pancreata from adult rats that display
low levels of TRH contain very low, barely detectable
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FIG. 2. PAMase (v- -A) activity and TRH (v-*) and TRH
precursor (o-.-o) levels in 4-day-old rat pancreatic mitochondrial/
secretory granule preparation fractionated on Percoll gradients. The
0.4-ml fractions were assayed for PAMase activity according to
Eipper et al. (22) and for TRH (23) and TRH precursor (9). TRH
precursor levels are expressed as ng of TRH-OH generated after
sequential enzymatic treatment with trypsin and carboxypeptidase
A.
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amounts of PAMase activity (20). Pancreata from neonatal
rats contain very high PAMase activity, which peaks on the
third postnatal day. The ontogenetic evolution of PAMase
activity in the pancreas is parallel to that of TRH in this
tissue, suggesting a direct relationship between both sub-
stances. The colocalization of TRH, its precursor, and
PAMase activity in the subcellular fractions of pancreatic
tissue adds further evidence for a role of PAMase activity in
the biosynthesis of TRH. In addition, pancreatic PAMase
activity is able to generate TRH, when incubated with
<Glu-His-Pro-Gly, a tetrapeptide that has been identified as
a repetitive sequence present in the TRH precursor (11). This
tetrapeptide has been utilized as a substrate to demonstrate
the capacity of hypothalamic and hypophysial PAMase to
generate TRH (19, 25, 26).
The reduction of PAMase activity in the pancreata of
streptozotocin-injected rats has two implications. First, it
suggests that, like insulin and TRH (27, 28), part of this
enzymatic activity is contained in the beta cells of the islets
of Langerhans. Second, it indicates also that a significant
fraction of PAMase activity is present in pancreatic tissue
outside of the beta cells, in other cells of the islets of
Langerhans and/or in exocrine pancreas. Indeed, peptide
amidation activity has been described in exocrine tissues,
including the rat exocrine pancreas (29). PAMase activity
may be directed toward proteins other than TRH precursor
in the pancreas. This activity has been assumed to be
involved in the amidation process of various pituitary pep-
tides, such as a-melanocyte-stimulating hormone (a-MSH),
oxytocin, and vasopressin. PAMase activity in the pancreas
may have also a broad specificity and be involved in the
synthesis of other peptides. The list of peptides ending with
amidated residues and present in the pancreas includes
vasoactive intestinal polypeptide, secretin, gastrin-releasing
peptide, neuropeptide Y, pancreatic polypeptide (PP), and
gastrin. Detailed information on the postnatal evolution of all
of these peptides is not yet available. However, the evolution
of gastrin levels in the neonate rat pancreas strikingly follows
a pattern similar to that of TRH (30). The number of
PP-storing cells increases abruptly in 5- to 7-day-old rats (31).
Interestingly, the plateau of PAMase activity between the
fifth and seventh day occurs during the period of maximum
increase of PP cell number.
Other data from our group indicate that the ontogenetic
evolution of TRH precursor in the pancreas parallels that of
PAMase activity and TRH (unpublished results). Thus, it
appears that the levels of a neuropeptide precursor (TRH
precursor) and of an enzymatic activity (PAMase activity)
involved in the posttranslational modifications of this pre-
cursor are similarly regulated in the neonate rat pancreas.
The COOH-terminally amidated peptide, a-MSH is normally
produced by the neurointermediate lobe ofthe pituitary gland
through the processing of proopiomelanocortin by several
proteolytic enzymes, acetylating enzyme, and PAM activity.
It has been reported that glucocorticoids decrease proopio-
melanocortin levels and PAMase activity in At-T20 cells (32).
No information is available on the effects of glucocorticoids
on the activity of other enzymes involved in the processing
ofproopiomelanocortin. It must be noted that At-T20 cells do
not synthesize a-MSH, probably because proteolytic cleav-
ages of proopiomelanocortin do not give rise to a suitable
substrate for PAMase activity in these cells. Hence, the
function of PAMase activity in At-T20 cells is not yet
determined. Nevertheless, it is interesting to note that the
syntheses of peptide precursors and PAMase activity are
coregulated in two different tissues.
It has been shown that bovine neurointermediate pituitary
contains two forms ofPAMase activity that differ in apparent
molecular weight (33). Further studies are needed to char-
acterize and purify PAMase in the pancreas. These investi-
gations would allow the determination of the reaction mech-
anism of this enzyme and the development of antibodies and
cDNA probes, and hence the ability to study the localization
and regulation of this (these) enzyme(s).
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